VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Voyager Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$2.05+0.15 (+7.89%)

Close on Oct 19, 2026

Market cap: $124.12M
P/E (TTM): –
Dividend yield: –

Voyager Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	40	80	250	41	37	171	104	7.62	10	14	17	–
Research & Development	135	127	92	61	74	109	120	65	62	42	28	8.90
General & Administrative	38	36	36	31	37	35	36	34	20	13	9.91	5.47
Operating Expenses	172	163	128	92	111	144	156	99	82	56	38	14
Operating Income	-132	-83	122	-51	-74	27	-52	-91	-72	-41	-20	-14
Other Non-Operating Income	12	19	12	4.45	2.42	9.36	8.08	2.63	1.17	1.16	-9.42	-1.95
Merger & Restructuring Charges	–	–	–	–	2.60	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-0.14	-0.51	-0.18	-0.38	–	–	–	–	–	–	–	–
Pretax Income	-120	-64	134	-46	-71	37	-44	-88	-71	-40	-30	-16
Income Tax Expense	0.14	0.67	1.41	0.02	–	–	–	-0.18	–	0.05	0	–
Net Income incl. Noncontrolling Interests	-120	-65	132	-46	-71	37	-44	-88	-71	-40	–	–
Net Income	-120	-65	132	-46	-71	37	-44	-88	-71	-40	-30	-16
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	1.25	–
Net Income to Common	-120	-65	132	-46	-71	37	-44	-88	-71	-40	-38	-18
EPS (Basic)(per share)	-2.04	-1.13	3.08	-1.21	-1.89	0.99	-1.21	-2.75	-2.64	-1.59	9.14	27.83
EPS (Diluted)(per share)	-2.04	-1.13	2.97	-1.21	-1.89	0.98	-1.21	-2.75	-2.64	-1.59	9.14	27.83
Shares Outstanding (Basic, Weighted)(shares)	59	58	43	38	38	37	36	32	27	25	4.19	0.64
Shares Outstanding (Diluted, Weighted)(shares)	59	58	45	38	38	37	36	32	27	25	4.19	0.64
Dividend per Share(per share)	–	–	–	–	0.00	0.00	0.00	0.00	–	–	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -340.1%
Net margin: -312.6%
Return on equity, FY2025: -48.3%

Financial strength

Current ratio: 7.51
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 214.4%

Valuation

P/E ratio: –
Price to sales: 3.60
Price to book: 0.80
Dividend yield: –